A dozen phase III trials in neurology were published in 2018, many of which led to FDA approvals. The following is a summary of the study results.
Galcanezumab is a monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) ligand for migraine prophylaxis. Efficacy was evaluated versus placebo in three phase III studies in episodic migraine (EVOLVE-1 and -2, n=1773) and in chronic migraine (REGAIN, n=1113) (Forderreuther et al. J Headache Pain 2018;19:121; free full text at https://thejournalofheadacheandpain.biomedcentral.com/track/pdf/10.1186/s10194-018-0951-2).